| Factor Information | |
|---|---|
| Data ID | 1429 |
| Factor | preoperative mPAP |
| Description | N/A |
| Biomarker | NA |
| Classification | E9 (physiological factor - hemodynamic parameter) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | PAH patients |
| p Value | 0.02 |
| Conclusion | Preoperative mPAP was higher in IPAH patients than that in RPAH patients. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 101 |
| CHD Type | isolated CHD |
| CHD Subtype | CHD with PAH |
| Reference | |
|---|---|
| PMID | 26791551 |
| Year | 2016 |
| Title | Pathologic markers for evaluation of reversibility in pulmonary hypertension related to congenital heart disease |
| Sample | ||
|---|---|---|
| Population | children, adolescent, adult | |
| Source | data | |
| Region | Beijing, China | |
| Method | Pearson χ 2 test | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | irreversible pulmonary hypertension-IPAH(Treatment) | reversible pulmonary hypertension-RPAH(Control) |
| Number | 4 | 24 |
| Age | 46.3±14.5 years | 26.3±17.0years |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 53.3±23.4 mmHg | 34.1±12.7mmHg |
